Fig. 2

MIS416 treatment induced recruitment of blood-derived myeloid cells to the CNS and induced chemokine expression by CNS myeloid cells. a CD45.2 mice were irradiated and received bone marrow transplant from CD45.1 donors, and 8 weeks later mice received MIS416 intrathecally and 24 h post injection brains were isolated and analyzed. Representative flow cytometry profile showing the distribution of CD45.1^high cell population in the CNS of unmanipulated (Unm), control (Ctrl) and MIS416-treated CD45.2 recipient mice at 24 h. b Expression of CXCL1 and CXCL2 in the CNS from MIS416 treated or control mice at 4 and 24 h was analyzed by RT-qPCR. Bar graphs show CXCL1 and CXCL2 gene expression at indicated times. b Fold changes in CXCL1 and CXCL2 mRNA in sorted CD45^dimCD11b + microglia and CD45^high cells from MIS416-treated mice compared to control mice, analyzed by RT-qPCR. c Expression of CCL2 and CXCL10 mRNA in the CNS from MIS416-treated or control mice at 4 h was analyzed by RT-qPCR. Bar graphs show CCL2 and CXCL10 gene expression. Data are presented as means ± SEM. (n = 3–5 per group). Results were analyzed using the two-tailed Mann-Whitney u-test; * p < 0.05, ** p < 0.01, *** p < 0.001